Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Department of Chemistry, School of STEM, Dillard University, New Orleans, LA, 70122, USA.
Med Chem. 2024;20(4):414-421. doi: 10.2174/0115734064275120231222111145.
Heparins are sulfated glycosaminoglycans that are used as anticoagulants to treat thrombosis. Heparins exhibit other potential therapeutic effects, such as anti-inflammatory, anti-viral, and anti-malarial effects. However, the strong anticoagulant activity of heparins poses a risk of life-threatening bleeding, limiting their therapeutic use for other diseases beyond thrombosis. To exploit the other effects of heparins and eliminate the bleeding risk, we explored an alternative polymer called lignosulfonic acid sodium (LSAS), which acts as a sulfonated heparin mimetic. LSAS targets factor XIa to exert an anticoagulant effect, and thus, unlike heparins, it is unlikely to cause bleeding.
This study investigated the multiple effects of LSAS to identify potential leads for complex pathologies treatment. A series of chromogenic substrate hydrolysis assays were used to evaluate the inhibition of three inflammation-related proteases by LSAS. Its chemical antioxidant activity against the system of ABTS/hydrogen peroxide/metmyoglobin was also determined. Lastly, the effect of LSAS on TNFα-induced activation of the NF-κB pathway in HEK-293 cells was also tested to determine its cellular anti-inflammatory activity.
The results showed that LSAS effectively inhibited human neutrophil elastase, cathepsin G, and plasmin, with IC values ranging from 0.73 to 212.5 μg/mL. Additionally, LSAS demonstrated a significant chemical antioxidant effect, with an IC50 value of 44.1 μg/mL. Furthermore, at a concentration of approximately 530 μg/mL, LSAS inhibited the TNFα-induced activation of the NF-κB pathway in HEK-293 cells, indicating a substantial anti-inflammatory effect. An essential advantage of LSAS is its high water solubility and virtual non-toxicity, making it a safe and readily available polymer.
Based on these findings, LSAS is put forward as a polymeric heparin mimetic with multiple functions, serving as a potential platform for developing novel therapeutics to treat complex pathologies.
肝素是一种硫酸化的糖胺聚糖,用作治疗血栓的抗凝剂。肝素具有其他潜在的治疗作用,如抗炎、抗病毒和抗疟疾作用。然而,肝素的强烈抗凝活性存在危及生命的出血风险,限制了其在血栓以外的其他疾病中的治疗用途。为了利用肝素的其他作用并消除出血风险,我们探索了一种替代聚合物,称为木质素磺酸钠(LSAS),它作为一种磺化肝素类似物。LSAS 靶向因子 XIa 发挥抗凝作用,因此,与肝素不同,它不太可能引起出血。
本研究调查了 LSAS 的多种作用,以确定治疗复杂疾病的潜在先导化合物。使用一系列显色底物水解测定法来评估 LSAS 对三种炎症相关蛋白酶的抑制作用。还测定了其对 ABTS/过氧化氢/高铁肌红蛋白体系的化学抗氧化活性。最后,还测试了 LSAS 对 TNFα 诱导的 HEK-293 细胞中 NF-κB 途径激活的影响,以确定其细胞抗炎活性。
结果表明,LSAS 有效抑制人中性粒细胞弹性蛋白酶、组织蛋白酶 G 和纤溶酶,IC 值范围为 0.73 至 212.5μg/mL。此外,LSAS 表现出显著的化学抗氧化作用,IC50 值为 44.1μg/mL。此外,LSAS 在约 530μg/mL 的浓度下抑制 TNFα 诱导的 HEK-293 细胞中 NF-κB 途径的激活,表明具有显著的抗炎作用。LSAS 的一个重要优势是其高水溶性和虚拟非毒性,使其成为一种安全且易于获得的聚合物。
基于这些发现,LSAS 被提出作为一种具有多种功能的聚合肝素类似物,可作为开发治疗复杂疾病的新型治疗药物的潜在平台。